Recursion Prices 61.54 Million New Shares At $3.25, Raising $200 Million Gross Before Fees
The offering is priced below the $3.74 last sale on October 14, and the new shares equal 10.3% of the count outstanding afterward.
Recursion Pharmaceuticals priced an offering of 61,540,000 Class A shares at $3.25 each, for $200,005,000 in gross proceeds, according to a 424B5 prospectus supplement dated Thursday. The company receives an estimated $187.2 million after underwriting discounts and offering expenses.
Price, size and proportion
The $3.25 price compares with a $3.74 last reported sale price on Nasdaq on October 14, 2026, a discount of 13.1% to that reference. Underwriting discounts and commissions come to $0.195 a share, or $12,000,300, leaving $188,004,700 before expenses.
The prospectus puts shares outstanding after the offering at 594,731,318, based on 533,191,318 outstanding as of June 30, 2026. The new shares equal 10.3% of that post-offering count. The count excludes stock options, restricted stock units, plan reserves and other shares the document lists.
Buyers in the offering face immediate dilution of $2.21 per share in net tangible book value, the prospectus says. In Thursday after-hours trading, the stock traded at $4.14.
What the money is for
Most of the proceeds are earmarked for current preclinical and clinical work, notably "a registrational study for REC-4881 in FAP" and expansion cohorts testing REC-1245 in solid tumors. Smaller uses include platform development, extending cash runway, acquisitions or strategic investments, and general corporate needs. It adds that it has no current agreements for any specific acquisitions or strategic investments.
The company believes existing cash, cash equivalents and restricted cash, plus these proceeds, will fund operations into 2029. Cash stood at approximately $561 million as of September 30, 2026, a preliminary estimate that the company's auditor has not reviewed. That figure includes about $86 million in net proceeds from selling 23,696,330 shares through its at-the-market program during the quarter.
Data released alongside the sale
The supplement repeats program news from Thursday. For REC-4881 in familial adenomatous polyposis, 87% of 16 efficacy-evaluable patients had reductions in total polyp burden, with a 47% median reduction at week 13. The company anticipates starting a registrational trial in 2027, pending FDA discussions.
For REC-1245, 11 of 12 patients (91.7%) at the 45 mg or 65 mg starting doses achieved disease control at eight weeks. The 65 mg dose exceeded the maximum tolerated dose, and the company chose 45 mg for expansion cohorts.
Sanofi also optioned the first candidate from its collaboration with Recursion, triggering a $10 million milestone payment.
What to watch
Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Evercore ISI and Needham & Company are the underwriters. They expect to deliver the shares against payment in New York on or about October 16, 2026. The full REC-4881 dataset will be presented on Monday, November 2.
Delivery of the shares is expected on or about October 16, 2026, when the money changes hands.